STADA Arzneimittel — Investor Presentation (August 2025)
110 slides from STADA Arzneimittel's investor presentation, Aug 28, 2025
Slide 1: Caring for People's Health – Company Presentation
Caring for People’s Health Company Presentation 28 August 2025
Slide 2: Important Notice
Important Notice THIS PRESENTATION AND ITS CONTENTS ARE CONFIDENTIAL AND ARE NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO OR FROM THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, JAPAN OR ANY JURISDICTION WHERE SUCH RELEASE, PUBLICATION OR DIS
Slide 3: Important Notice
Important Notice The information contained in this Presentation is not to be viewed from nor for publication or distribution in nor taken or transmitted into the United States of America, its territories and possessions, any State of the United States, and the District of Columbia (“United States”),
Slide 4: Important Notice
Important Notice This Presentation includes certain consolidated financial information of Nidda German Topco GmbH and, in addition, includes certain financial measures that are not recognized by IFRS or any other generally accepted accounting principles, including measures based on or derived from c
Slide 5: Important Notice
Important Notice This Presentation, where indicated, includes information from different sources. The information derived from market research information provided by IQVIA and its affiliated companies (“IQVIA”) includes data from the following data offerings: IQVIA MIDAS®, IQVIA Consumer Health Cus
Slide 6: Important Notice
Important Notice "Sanofi Commercial Alliance": Involves the following brands that are presently listed in the data under Sanofi instead of STADA: (Bulgaria) Essentiale; (Estonia) Magne B6, Maalox, No Spa, Essentiale, Ipraalox, Finalgon, Dulcolax; (Finland) Bisolvon, Nasacort, Telfast, Laxoberon; (Fr
Slide 7: Today's presenters
Today’s presenters 30y 20y 20y experience experience experience Peter Goldschmidt Boris Döbler Ingo Schachel Chief Executive Officer Chief Financial Officer Head of Investor Relations Joined in 2018 Joined in 2019 Joined in 2024 PREVIOUS EXPERIENCE PREVIOUS EXPERIENCE PREVIOUS EXPERIENCE (1) Source:
Slide 8: H1 Highlights
H1 Highlights
Slide 9: H1 2025 Update Summary
H1 2025 Update Summary STADA H1 2025: Fully on track for FY guidance after sustained outperformance in H1, Specialty outlook raised due to continued strong growth in Innovative and biosimilars Key highlights in H1 2025 1 Growth1 of +6% in Adj. cc Revenues with an attractive Adj. cc EBITDA2 margin of
Slide 10: Strong momentum along our five strategic priorities
H1 2025 Update Strategic Priorities Strong momentum in 2025 along our five strategic priorities: Minimal impact from US tariffs or regulatory changes; continued high pace of value-generating BD&L activities Strong Portfolio Low-cost operating Efficient and reliable Growth marketing and sales acceler
Slide 11: Accelerated growth in H1 2025 outpacing peers in all segments
H1 2025 Update Revenues STADA with further accelerated growth in H1 2025 outpacing peers1 in all segments H1 Adj. cc Revenues2,3 (€m) Growth (%) • Growth accelerated with notable Q2 topline +6% 2,123 growth in CHC (+6%) and Generics (+4%) driven by recent launches 2,010 • Continued strong growth in
Slide 12: Adj. cc EBITDA at a new record level in H1 2025
H1 2025 Update EBITDA Adj. cc EBITDA at a new record level in H1 2025 with pleasing double-digit growth in Specialty H1 Adj. cc EBITDA1,2 (€m) Adj. cc EBITDA Margin 22.6% • Continued 5% Adj. cc. EBITDA growth in H1 2025, despite high prior year base (one-offs in H1 2024 results) 481 • FY Adj. cc EBI
Slide 13: Consumer Healthcare unimpacted by US headwinds
H1 2025 Update Consumer Healthcare Consumer Healthcare unimpacted by US headwinds: Growth re-accelerated in Q2 2025 with outperformance vs. peers1 Adj. cc Revenues2 (€m) Adj. cc EBITDA2 (€m) Adj. cc EBITDA Margin YoY growth in % ~5% growth excluding • Excluding C&C/Seasonal Q1’25: - 1% C&C/Seasonal
Slide 14: Generics: Solid MSD% growth in Q2
H1 2025 Update Generics Generics: Solid MSD%1 growth in Q2 fueled by strong launches and high exposure to the resilient & growing EU Generics market Adj. cc Revenues2 (€m) Adj. cc EBITDA2 (€m) YoY growth in % Adj. cc EBITDA Margin Q1’25: + 1% 25.4% • Adj. cc Revenues up +2% against Q2’25: + 4% high
Slide 15: Specialty: Strong double-digit growth
H1 2025 Update Specialty Specialty: Strong double-digit growth with excellent contribution of recent launches, e.g. Ustekinumab, Nilotinib, Paclitaxel & strong growth of Innovative medicines Adj. cc Revenues1 (€m) Adj. cc EBITDA1 (€m) YoY growth in % Adj. cc EBITDA Margin Q1’25: + 22% 33.6% • Contin
Slide 16: Accelerated and profitable organic revenue growth in Q2
H1 2025 Update STADA Group STADA with accelerated and profitable organic revenues growth in Q2 – fully on track for 2025 guidance Adj. cc H1 Revenues and Adj. cc EBITDA (€m) Q2 Adj. cc Revenues growth of +7%1 with: %- vs H1'25 H1'24 • Growth firmly in MSD-HSD% growth corridor for the group Adj. cc
Slide 17: Adj. cc EBITDA evolution throughout the year
H1 2025 Update Quarterly Progression Adj. cc EBITDA-evolution throughout the year: On track for FY’25 Guidance Adj. cc EBITDA H1 vs H2 – actual results 20241 Reminder: Half-yearly EBITDA-pattern 2024 52% 48% • H1 2024 unusually high based on strong seasonal sell-in and favorable one-time effects 457
Slide 18: Fully on track for 2025 company guidance
H1 2025 Update Guidance 2025 Fully on track for 2025 company guidance – Specialty growth guidance raised after strong and sustained H1 trend reflecting successful launch performance Guidance: € or growth rate percentage ranges 2024 Results: KPIs: 2025 Forecast Comment on range of outcome: Adj. Reven
Slide 19: STADA's mid-term guidance
H1 2025 Update Mid-term Guidance STADA’s mid-term guidance: Confident to deliver mid- to high single-digit topline and margin accretive Adj. cc. EBITDA growth; additional upside potential from M&A/BD&L Guidance: € or growth rate percentage ranges 2025 Forecast 2024 Results KPIs: Mid-term Guidance (Q
Slide 20: Cash generative business model
H1 2025 Update Cash conversion Cash generative business model – H1 with temporary inventory increase related to strong Sx and Gx launches and bridging stock for strategic products Core Free Cash Flow1 (€m) H1’24 H1‘25 1• Core Free Cash Flow of €166m in H1 2025 Adj. cc EBITDA 100% 457 100% 481 2• Cha
Slide 21: STADA – people, portfolio & pipeline for continued growth
STADA – people, portfolio & pipeline for continued growth
Slide 22: STADA's management team track record
Growth Culture People STADA’s management team has a strong success track record across all segments Name & Position1 Experience Sector expertise Consumer Healthcare Generics Specialty Peter Goldschmidt 2 Chief Executive Officer ✓ ✓ ✓ Boris Döbler Chief Financial Officer ✓ ✓ ✓ Simone Berger Chief Peo
Slide 23: Strong and innovative portfolio with recent launches
Growth Culture Portfolio STADA has strong and innovative portfolio with attractive in-market products and successful recent launches Already launched Innovative APO-GO® • Strong growth track record of in- market Innovative products Kinpeygo and Lecigon Biosimilars • Biosimilars growth boosted by suc
Slide 24: Rich launch pipeline for 2026 and beyond
H1 2025 Update Pipeline STADA has a rich launch pipeline across all segments for 2026 and beyond 2026+ Innovative Strong funnel of 185 deals being screened • 50 new BD&L deals signed in H1 2025 (thereof 41 in-licensing) • >260 projects under Biosimilars development (thereof >150 Tocilizumab internal
Slide 25: STADA's Strategy Summary
STADA’s Strategy Summary Key financial & value creation highlights – Extending our track record of outperformance in H1 2025 and FY 2025 & tapping additional value creation potential • Strong track record of outperforming European markets1 in all three segments 2021-24 • Demonstrated growth in attra
Slide 26: A distinctive investment case in Healthcare
Focused on large, mostly non-cyclical markets growing mid- 1 single to low-double-digit Track-record of outperforming relevant markets1 with leading 2 positioning and attractive risk profile Differentiated strategy for Consumer Healthcare, Generics and Specialty – 3 STADA – with symbiotic nature of
Slide 27: A distinctive investment case in Healthcare
STADA – A distinctive investment case in Healthcare General introduction for investors
Slide 28: A leading supplier of healthcare products
A leading supplier of healthcare products across Self-Care (Consumer Healthcare), Primary Care (Generics) and Specialty Care (Specialty), fully integrated across global product development, procurement and manufacturing, and commercialization
Slide 29: STADA – A leading supplier of Healthcare products
Investment highlights Who We Are STADA – A leading supplier of Healthcare1 products Key financials 2024 Revenues by segment2 Revenues by product2,3,4 Revenues by country2,3,5 Consumer Uzpruvo® Kinpeygo® Specialty Corpos® €4.1bn Versatis® Healthcare Movymia® Nizoral® Rest of World6 Revenues (“Sx”) Hu
Slide 30: Transformation of a ~130 year heritage company since 2017
Investment highlights Where we come from Since 2017, significant transformation of a ~130 year heritage company into a leading supplier of Healthcare1 products Revenues (€bn) Adj. EBITDA (€bn) 6 1.5 CAGR CAGR 1.3 +12% +17% 5 4.1 3.7 1.1 4 3.3 0.9 2.9 0.9 0.8 3 0.7 0.5 0.7 2 0.5 0.3 1 0.1 0 2017 2021
Slide 31: All three segments with strong topline and EBITDA growth
Financials Segments 4Y All three segments with strong topline and adj. EBITDA growth over the years and strong profitability of ~25% in CHC, ~24% in Gx and ~33% in Sx Group Consumer Healthcare Generics Specialty +12%/+11% +16%/+13% +8%/+8% +16%/+16% Total / organic1 CAGR 3,735 4,059 1,489 1,537 1,65
Slide 32: Strong organic growth driven by volume and launches
Financials Segments 4Y Strong organic growth driven by volume and product launches in all three segments, Consumer Healthcare with highest price increases and inorganic growth1 Consumer Healthcare Generics Specialty +16% +8% CAGR +16% 870 1,497 1,652 749 1,489 1,537 1,307 1,414 603 1,281 559 986 Rev
Slide 33: Resilience based on diversification and manufacturing footprint
Investment highlights Diversified platform STADA's resilience based on diversification and manufacturing footprint Diversification of Segments and Broad Based Manufacturing Well-positioned regarding US Tariff Products Capacity to Ensure Supply Reliability Challenges 2024 Revenues by product1,2 Overv
Slide 34: Large, growing, non-cyclical European Healthcare markets
Investment highlights Markets Focused on large, growing and mostly non-cyclical European Healthcare markets Consumer Healthcare Market Generics Market Specialty Market European Consumer Healthcare market, EUR bn gross European Generics market, EUR bn gross sales European Specialty market, EUR bn gro
Slide 35: Consistently outperformed European markets
Investment highlights Markets Consistently outperformed relevant European markets driven by strong organic growth Consumer Healthcare (38%1) Generics (41%1) Specialty (21%1) The fastest-growing major Consumer Health- A leading Generics player Attractive portfolio of Biosimilars, Specialty care compa
Slide 36: Three distinct strategies to differentiate in each segment
Investment highlights Segments Three distinct strategies to differentiate STADA in each segment Consumer Healthcare Generics Specialty • Driving portfolio of Local Hero brands1 • Deliberate geographic footprint (e.g. no • Build and grow portfolio with complex, across OTC categories and STADA USA) wi
Slide 37: STADA's Strategy
STADA’s Strategy
Slide 38: Clear strategic framework with Growth Culture at its core
STADA’s Strategy Strategic Framework Our performance is based on a clear strategic framework with Growth Culture at its core Purpose “Caring for people’s health as a trusted partner” “To be the partner of choice in Consumer Health, Generics and Vision Specialty continuously outgrowing the industry i
Slide 39: Strong commercial focus on Europe and selected Emerging Markets
STADA’s Strategy Where to play STADA: Strong commercial focus on Europe and selected Emerging Markets Commercial focus: Europe (Revenues) Emerging Markets (Revenues) 2021 2024 2021 2024 Western Europe Eastern Europe Germany Source: Company information 39
Slide 40: Highly complementary financial profile across segments
STADA’s Strategy Summary All three segments have a highly complementary financial profile Consumer Healthcare Generics Specialty Continued financial Peak Revenues Peak Revenues 1 Product lifecycle investments in long in first year in 5 to 10 years term brand building Limited 2 Cyclicality cyclicalit
Slide 41: Symbiotic effects across segments and value chain
STADA’s Strategy Summary STADA realizes symbiotic effects across the segments and along the entire value chain Synergy area Consumer Healthcare Generics Specialty Commerciali- 1 zation/GTM Broad and symbiotic coverage (e.g. shared field force) API1 and packaging material procurement, Logistics 2 Pro
Slide 42: Local Hero brands as a flexible growth platform
STADA’s Strategy CHC – Local Hero brands STADA’s portfolio of Local Hero brands1 provides a flexible growth platform Number of Local Hero1 brands2 STADA’s Local Hero1 brands3 Europe and Eurasia By country 242 21 Other4 60 19 229 18 7 16 7 8 15 8 220 9 15 9 9 10 11 138 By category Cough & Cold 120 37
Slide 43: Leading in market share gains in European CHC
STADA’s Strategy CHC – Market STADA is leading in terms of market share gains in European market 2019: 2023: 2024: STADA #10 in the market with 1.7% market share1 STADA #4 in the market with 2.9% market share1 STADA #4 in the market with 2.9% market share1 European market share by gross sales (2019)
Slide 44: Ranking #1 on Innovation Freshness Index
STADA’s Strategy CHC – Innovations STADA is ranking #1 Innovation Freshness Index1, ahead of all key competitors2 Innovation Freshness Index1 Key Drivers % MAT Sales generated by last three years launches from the total MAT sales in March 2025 • Innovation pipeline is fueled by internal / external d
Slide 45: Accelerating growth via e-Commerce
STADA’s Strategy CHC – e-Commerce Accelerating growth via e-Commerce in profitable high growth markets E-Com Revenues1 STADA's e-Com acceleration playbook 1 Focus e-Com efforts on countries with substantial e-Com size already and future growth potential 25% CAGR >10% of total Concentrate on e-Com su
Slide 46: E-commerce growth in Germany & China
STADA’s Strategy CHC – e-Commerce E-commerce growth in Germany & China: A growth engine for STADA Consumer Healthcare Germany eCommerce Revenues Development China eCommerce Revenues Development • e-Commerce revenues CAGR of +21%1 from 2021 • e-Commerce revenues CAGR of +79%1 from 2021 to 2024 to 202
Slide 47: One of the fastest growing global CHC companies
STADA’s Strategy CHC – Market STADA is one of the fastest growing global CHC companies 2024: 2024: Top 10 global CHC players - Market share by value1 Top 10 global CHC players – Gross sales growth by value vs PY1 5.7% 9.8% 4.0% 7.5% 3.7% 4.4% 3.5% 4.3% 2.6% 3.0% 2.3% 2.6% 1.1% 2.1% 1.1% 1.9% Top 10
Slide 48: Transforming brands is a key growth driver
STADA’s Strategy CHC – Local Hero brands Transforming brands is a key growth driver for STADA Consumer Healthcare Selected brand highlights Doubled revenues since From disinfection concentrate to a From diarrhea medicine to acquisition through innovation successful household brand popular electrolyt
Slide 49: European generics market more attractive than US
STADA’s Strategy Gx – Market The European market is a fundamentally more attractive market than the US market Characteristics of the EU & US Market Characteristics of the EU Generics market Characteristics of the US Generics market Market access & EMA >30 FDA regulatory Central regulatory authority
Slide 50: Distinct strategic differentiators vs. competitor archetypes
STADA’s Strategy Gx – STADA Positioning STADA has distinct strategic differentiators vs. all competitor archetypes Strategic differentiators of STADA vs. competitor clusters Tailored business model Global Regional Local Indian • Strong commercial platform based on players champions champions players
Slide 51: Market opportunity expanding on blockbuster LoEs
STADA’s Strategy Gx – Market STADA’s market opportunity is set to expand on the back of blockbuster LoEs Value of non-Specialty LoEs1 in Europe (originator gross sales, €bn) Highlights Forecasted 5.6 • Full visibility on LoE pipeline based on 5.3 originator drugs' patent protection 5.1 €4.6bn timeli
Slide 52: Track record of first-to-market launches
STADA’s Strategy Gx – Launch Performance STADA has a strong track record of first-to-market launches with potential for further growth with broad coverage of future LoEs STADA’s robust launch performance Strong coverage and launch capabilities Market value coverage for top 20 LoE launches in Europe
Slide 53: Specialty portfolio balanced across high growth and stability
STADA’s Strategy Sx – Overview STADA Specialty portfolio is well balanced with high-growth and high stability STADA Specialty Revenues (including product category split for 2024) (€m) Description of product categories Higher Innovative 870 Drugs w/ market exclusivity addressing unmet clinical needs.
Slide 54: Movymia and Oyavas gained significant market share
STADA’s Strategy Sx – Biosimilars Movymia® (Teriparatide) and Oyavas® (Bevacizumab) have taken significant market share showcasing the strength and breadth of STADA biosimilars Total European gross sales (€m) CAGR Total European gross sales (€bn) CAGR 2021 to 2024 2021 to 2024 253 212 194 203 201 22
Slide 55: Steady stream of high-value biologic LoEs
STADA’s Strategy Sx – Biosimilars Steady stream of high-value biologic LoEs is on the horizon and STADA is well positioned as partner of choice for biosimilars Biosimilar LoE Pipeline Comments LoE value incl. STADA's coverage (€bn)1 • STADA proactively monitors upcoming Biologics LoEs and 22.3 asses
Slide 56: Covering expanding specialty generics LoEs with strong partners
STADA’s Strategy Sx – Specialty Generics STADA covers the majority of expanding specialty generics LoEs with strong partners Specialty Generics LoE Pipeline1 Comments LoE value incl. STADA's coverage (€bn) • Strong track record of first-to-market launches based on development, BD&L, and regulatory c
Slide 57: Deal funnel of Innovative Specialty in-licensing opportunities
STADA’s Strategy Sx – Innovative Specialty Strong deal funnel of Innovative Specialty in-licensing opportunities for the near future Deal funnel (n=185) Comments Number of products under evaluation split by therapeutic areas and stage of development Others Nephrology Neurology • Enhance the product
Slide 58: Appendix – Consumer Health
Appendix Consumer Health
Slide 59: Consumer Healthcare Overview
Consumer Healthcare Overview STADA – The fastest-growing Consumer Healthcare Business in Europe (2022-2024)1, driven by specific Go-To-Market approach 16% 13% #4 Other Revenues CAGR Organic Revenues in CHC Europe2 56% CAGR 2021-2024 5% 2021-2024 5% €1.5bn Spain 4% Revenues 2024 Kazakhstan 4% 5% Neth
Slide 60: Large, growing European Consumer Healthcare market
Consumer Healthcare Market Addressing the large, growing and resilient European Consumer Healthcare market European Consumer Healthcare market (€bn) Accelerating growth drivers CAGR +1.6% +4.6% +1.7% +2.1% +3.8% Increasing proportion of older people and population growth +6.2% 4 46 3 8 39 Increased
Slide 61: Strong double-digit growth across Europe
Consumer Healthcare Regions Delivering strong double-digit growth across Europe STADA Consumer Healthcare Revenues (€bn) 2.5 Organic CAGR CAGR 21-241 +13% Others 18% Serbia 15% 2 CAGR +16% Poland 6% 1.5 1.5 1.5 France 21% 1.3 Belgium 10% 1 1.0 Kazakhstan 42% Spain 13% Italy 8% 0.5 Netherlands 30% UK
Slide 62: Local operational focus is a competitive advantage
Consumer Healthcare Strategy & Value pillars STADA’s local operational focus is a competitive advantage STADA's strategy Typical industry strategy Local vs. HQ Local entrepreneurship vs Central headquarters driven with lean headquarters Brand type Local Hero brands vs Global brands Brand activation
Slide 63: Brand portfolio covers all main consumer health categories
Consumer Healthcare Portfolio STADA’s brand portfolio covers all main consumer health categories Cough & Cold Derma Pain & Relief Gastro VMS¹ Other CHC • Nasal decongestant • Anti-dandruff • Antivaricose • Laxatives • Mineral supplements • Sleeping remedies • Cough relief • Wound healing • Muscular
Slide 64: Strong commercial infrastructure across Europe
Consumer Healthcare Marketing & Sales Capabilities STADA with strong commercial infrastructure covering almost all countries in Europe as well as Eurasia and selected EM1 covering est. ~100,000 pharmacies STADA covers >402 countries with ~2,300 internal sales force FTEs3 Significant sales power & pl
Slide 65: Nizoral: Reactivation of brand
Consumer Healthcare Local Hero brands Nizoral: Reactivation of brand by impactful activation and portfolio expansion Nizoral Revenues Key drivers CAGR 21-24 (%) 1 2019 – Launch of international campaign +24% 2 2023/24 – Line extensions: Daily range 3 2024 – Acquisition of Nizoral Cream in EMEA 2021
Slide 66: Zoflora: UK's #1 homecare disinfectant brand
Consumer Healthcare Local Hero brands Zoflora: UK’s #11 homecare disinfectant brand and Top 51 Cleaning brand in the UK Zoflora Revenues Key Launches CAGR 21-24 (%) 2021/22 Launch outside of disinfectant category 1 with activation via digital channels +7% 2 2023 Launch of floor and carpet cleaning p
Slide 67: Elotrans: From diarrhea to lifestyle
Consumer Healthcare Local Hero brands Elotrans: From diarrhea to lifestyle – a popular hydration and electrolyte solution Elotrans Revenues Key drivers CAGR 21-24 (%) 1979 – Launch of Elotrans - German STADA heritage brand 1 OTC solutions for treating dehydration resulting from diarrhea +62% 2 2023
Slide 68: Local Hero playbook accelerates growth
Consumer Healthcare Local Hero brands STADA’s proven Local Hero playbook accelerates growth through localized strategies STADA's brand acceleration levers Select brand examples Brand (re)activation awake dormant equity to appeal to consumers and pharmacies Within a brand Brand strengthening to maxim
Slide 69: #1 deal maker in Consumer Healthcare
Consumer Healthcare M&A STADA is the #1 deal maker in Consumer Healthcare1 and partner of choice for those looking to divest brands >200 brands acquired across all segments between 2018 and 2024 Critical M&A CHC Success Factors • Experienced integrator of brands into broader platform • Proven playbo
Slide 70: Opportunity to wake up >130 Sleeping Beauty brands
Consumer Healthcare Sleeping Beauty brands Prime opportunity to wake-up a further >130 Sleeping Beauty brands Selected Sleeping Beauty brands1,2 STADA’s Sleeping Beauty playbook Sleeping Beauties Cough Pain & & Cold Relief Gastro to be accelerated via proven playbook 1 Identify neglected brands with
Slide 71: Product development drives growth in Consumer Healthcare
Consumer Healthcare Product launches Product development is a differentiator for STADA and a key driver of growth in Consumer Healthcare Revenue growth from launches Launches by category 2024 Pain Cough & Derma Gastro VMS Hygiene Other & Cold Relief Baltics, >4% Nordics, Netherlands, Slovakia, Slove
Slide 72: Digital capabilities drive customer engagement
Consumer Healthcare Digital capabilities STADA's digital capabilities drive a high level of engagement with customers Digital medium Metric1 Description Example >500m impressions p.a. Company & brand webpages tailored Local Hero 531 to engage with consumers and enable Websites them to purchase on- o
Slide 73: Consumer Healthcare Key Takeaways
Consumer Healthcare Summary Key Takeaways 1 STADA is the fastest-growing company among the top 10 global CHC players (2022- 2024)1, ranked #42 in the attractive €39bn European Consumer Healthcare market (2024) 2 Proven playbook with >240 Local Hero brands and the opportunity to wake up >130 Sleeping
Slide 74: Appendix – Generics
Appendix Generics
Slide 75: Generics Overview
Generics Overview STADA – A leading Generics player in Europe and a growing business in Eurasia and Emerging Markets Spain 8% #4 ~85% 7% France organic player Europe, historic2 +targeted3 7% Revenues CAGR leading position Loss of Exclusivity Serbia 8% €XXXm (2021-2024) in key markets1 (LoE) coverage
Slide 76: Large, growing, fragmented European Generics market
Generics Market STADA addresses the large, growing, complex, fragmented and highly attractive European Generics market …requiring deep local skill and …and fragmented with competitive Large and growing market… localized GTM1 approach… landscape Gross sales by geography, €bn Illustrative indication o
Slide 77: Market growth expected to accelerate on LoEs
Generics Market Market growth is expected to accelerate based on a large profit pool of LoEs European Generics market 2019-2028E, gross sales (€bn) 5.3% CAGR 5 34 4.7% CAGR 27 1 0 5 22 1 0 Further potential upside through increased Gx penetration and potential easing of price pressure 2019 Volume Pr
Slide 78: Positioned to benefit from increasing Generics penetration
Generics Market STADA is well positioned to take advantage from increasing Generics penetration Generics penetration by country Untapped off-patent market Bn std. units of Generics vs. total volume (incl. non-Generics) 2024 • Generics accounting for ~68%1 of vs. 2019 +7.9 +1.1 +1.6 +5.9 +1.6 +3.4 +6
Slide 79: #4 Generics player in Europe with focus on retail
Generics STADA Positioning STADA is the #4 Generics player in Europe with a deliberate focus on retail Generics in attractive geographies Generics Revenues (€bn) Strong focus on Europe vs. 6% Gx market gross sales CAGR(2) • STADA is the #4(3) Generics player in Europe with 8 top-3 positions across E
Slide 80: Generics platform with tailored GTM models
Generics STADA Positioning STADA with strong Generics platform across markets due to highly tailored GTM models and excellent local commercial execution Retail segment only Every market has local channel differences… …requiring a differentiated approach to GTM strategy Nordics Germany UK Excellent c
Slide 81: Broad INN portfolio covering all therapeutic areas
Generics STADA Positioning STADA’s broad and comprehensive INN portfolio covers all therapeutic areas1, with over 16k SKUs Nervous Alimentary Tract & Anti- Urology & Musculo-Skeletal Respiratory Cardiovascular System & Pain Metabolism Infectives Sex Hormones System System • Diabetes • Asthma Select
Slide 82: Generics Key Takeaways
Generics Summary Key Takeaways STADA plays in the highly attractive European market: Large (€27bn generics gross 1 sales for 2024)1, accelerating in growth (~5% CAGR ‘24-’28E), with complex GTM framework and thus very profitable Leading positions in attractive and profitable markets (#4 player acros
Slide 83: Appendix – Specialty
Appendix Specialty
Slide 84: Specialty Overview
Specialty Overview STADA Specialty – Successfully developing and commercialising high-value treatments and delivering double-digit growth Innovative 16% 6/6 ~300 customer-facing Revenues CAGR first-attempt Specialty Gx1 FTEs in 30 (2021-2024) EMA approvals (incl. Branded Gx) markets2 €XXXm €0.9bn €X
Slide 85: Broad expertise across therapeutic areas
Specialty Overview STADA Specialty has broad expertise across therapeutic areas and proven ability to build new capabilities Product category Innovative Biosimilars Specialty Gx (incl. branded Gx) • Neurology: Advanced Parkinson’s Disease, Multiple • Rheumatology: Rheumatoid Arthritis • Multiple Mye
Slide 86: Dedicated Specialty M&S platform
Specialty M&S Platform Dedicated Specialty M&S platform that is tailored to product/market needs and is ready to launch additional complex products Go-to-market channels for STADA’s Specialty portfolio1 STADA Specialty M&S Footprint4 Nordics WE2 EE3 Country >250 Sales Reps & Key Account Managers ~25
Slide 87: Lecigon and Kinpeygo launches
Specialty Innovative Specialty Lecigon and Kinpeygo demonstrate STADA’s ability to launch complex innovative therapies and establish new standards of care Lecigon® Kinpeygo® Launch partner & competitive edge Advanced Parkinson’s disease Immunoglobulin A nephropathy (IgAN) Acquisition from Lobsor Pha
Slide 88: Large funnel of innovative therapy opportunities
Specialty Innovative Specialty STADA is evaluating a large funnel of opportunities for additional launch of innovative therapies STADA’s Innovative opportunity screening criteria Low develop- Attractive niche market Fit to portfolio ment risk Filter Close to launch Niche market/prescriber base, unat
Slide 89: Specialty Key Takeaways
Specialty Summary Key Takeaways 1 Specialty is the fastest-growing and strongly profitable segment within STADA and includes the product categories Innovative, Biosimilars and Specialty Generics 2 STADA's Specialty platform at-scale is ready to take advantage of favorable secular trends to launch ma
Slide 90: Appendix – Governance & ESG
Appendix Governance & ESG
Slide 91: Institutionalizing growth culture across the organization
Governance & ESG Growth Culture STADA is institutionalizing growth culture across the organization at all levels Examples how culture is hard-wired throughout STADA Examples how culture is soft-wired throughout STADA STADA+ Performance #CaringForYou STADA Expo management Growth mindset vehicle for S
Slide 92: Culture drives performance at STADA
STADA’s Strategy Growth Culture Culture drives performance at STADA 4 STADA - Acting in line with values 3"I amSTADA proud -toCaring work for forSTADA" employees 1 2 "I 2 amSTADA proud -toThe work for STADA" place to be NTM net sales growth (%) "I 1 amProud proud employees NTM net sales growth (%) t
Slide 93: Board of Directors with an Independent Chairman
ESG Governance Board of Directors based on Dutch Corporate Structure with an Independent Chairman Chair We envision a well-rounded Board of Directors that mirrors STADA’s commitment to excellence and innovation, aligning with best corporate governance practices, including those outlined in the Dutch
Slide 94: On track to achieve ambitious ESG targets
Governance & ESG ESG STADA is on track to achieve ambitious ESG targets 2024: 65% 2024: 0.35 >65% <0.30 renewable electricity by 2025 Lost Time Incident Rate (LTIR) by 2025 2024: -34% 2024: 80% 42% >90% reduction of GHG emissions by 2030 of spend (direct category) covered by (compared to 2020) EcoVa
Slide 95: Strong ESG ratings
Five Strategic Priorities ESG STADA has strong ESG ratings confirming our strong risk management processes and low ESG risk exposure Sustainalytics ESG rating1 EcoVadis ESG rating3 17.5 Sustainalytics ESG risk rating score 76/100 EcoVadis overall ESG score (Low ESG risk) (Advanced ESG score) Strong
Slide 96: ROI-driven make-or-buy process ensures competitive COGS
TechOps Competitive COGS STADA’s ROI driven make-or-buy decision process ensures competitive COGS Share of COGS1 Key pillars for competitive COGS • External Supply Organization (ESO) deployed globally • "External as internal" mindset FDF 2: External Sourcing Out-standing • Strong alliances and relat
Slide 97: Global manufacturing network in best-cost countries
TechOps Competitive COGS STADA’s global manufacturing network focuses on “best-cost countries” STADA internal manufacturing sites % share of Site Country CHC Gx Sx plants ‘241 High-cost 1 Bad Vilbel countries 31% 2 Uetersen Germany Best-cost 13 Miyun 3 Huddersfield countries 69% UK 4 Preston 5 Tulln
Slide 98: Six quality hubs drive no failure culture
TechOps Fit-for-purpose quality STADA’s six quality hubs drive “no failure culture” and supply resilience Quality footprint ready to support future growth … … and track record of no failure culture Bad Vilbel Vrsac Inspection Mumbai Shanghai Quality hub / Quality hub Audit hub Audit hub record shows
Slide 99: Appendix – Financials
Appendix Financials
Slide 100: Broad geographic footprint with strong growth
Financial Appendix Revenues geography Broad geographic footprint with vast majority of countries growing strongly Revenues by country (€m) – 20241,2 Comments % of Group Revenues CAGR 2021 – 2024 0 50 100 150 200 250 300 350 400 800 • Long list of countries with scale Germany 19% 15.2% and strong gro
Slide 101: Diversified portfolio with no product above 4% of revenue
Financial Appendix Revenues by product Diversified portfolio with no product larger than 4% of Group Revenues Revenues by product – 20241,2 Comments % of Group Revenues • CHC with over 1,000 products Nizoral® 2.0% (in the sense of brand or API- Consumer Zoflora® 1.5% name), thereof 241 brands with T
Slide 102: Key foreign currencies and guidance assumptions
Financial Appendix Currencies Key foreign currencies and assumptions behind guidance for 2025 – STADA with relatively limited FX-exposure Revenue in 2024 by currency (% of total) All other 19% • Over 60% of Revenues from entities with EURO as functional currency CHF 5% 7% • Other currencies making l
Slide 103: P&L: Continuous growth of revenues and EBITDA
Financial Appendix H1 2025 P&L P&L: Continuous growth of revenues and EBITDA in €m 2023 2024 Growth 1H’24 1H’25 Growth • Continuous strong topline-growth in all three Revenues 3,735 4,059 +9% 2,013 2,123 +5% segments Cost of sales 2,119 2,321 +10% 1,140 1,182 +4% Gross Profit 1,616 1,738 +8% 873 941
Slide 104: Gross Profit Adjustments: Mainly PPA effects
Financial Appendix Gross Profit 4Y Gross Profit Adjustments: Mainly PPA effects (in €m) 2021 2022 2023 2024 1H’24 1H’25 1⚫ Relates to the elimination of subsequent measurement effects of fair value step- ups included in the consolidated income statement of items initially recognized in Gross Profit
Slide 105: EBITDA adjustments
Financial Appendix EBITDA adjustments 4Y EBITDA adjustments: Minor adjustments to ensure better view of underlying performance (in €m) 2021 2022 2023 2024 1H’24 1H’25 1⚫ EBITDA adjustments for Purchase Price allocation effects mainly related to EBITDA 577 677 724 840 436 458 valuation-effects on the
Slide 106: IFRS P&L
Financial Appendix IFRS P&L P4Y IFRS P&L Consolidated income statement (€m) 2021 2022 2023 2024 1H’24 1H’25 • Over-proportionate gross profit Revenues 2,852 3,298 3,735 4,059 2,013 2,123 growth in H1 2025 based on price Cost of sales 1,675 1,879 2,119 2,321 1,140 1,182 increases and strong TechOps G
Slide 107: IFRS Balance Sheet
Financial Appendix IFRS B/S P4Y IFRS Balance Sheet Consolidated balance sheet - Assets (€m) Assets 2021 2022 2023 2024 1H’25 • Inventory increase in 2023 due Non-current assets 5,551 5,234 4,471 4,532 4,395 to deliberate investment to Intangible assets 4,862 4,500 3,686 3,584 3,467 secure supply rel
Slide 108: IFRS Balance Sheet (cont'd)
Financial Appendix IFRS B/S P4Y IFRS Balance Sheet (cont’d) Consolidated balance sheet - Equity & Liabilities (€m) Equity & Liabilities 2021 2022 2023 2024 1H’25 • Other provisions (current/non- Equity (215) (330) (1,142) (1,318) (1.490) current), since FY23 mainly Subscribed capital 0 0 0 0 0 inclu
Slide 109: IFRS Cash Flow Statement
Financial Appendix IFRS CFS P4Y IFRS Cash Flow Statement Consolidated Cash Flow statement (€m) 2021 2022 2023 2024 1H’24 1H’25 • Operating Cash Flow Result from continuing operations (244) (169) (124) (125) 0 (104) generation in previous years Depreciation, amortization and impairments net of revers
Slide 110: IFRS Cash Flow Statement (cont'd)
Financial Appendix IFRS CFS P4Y IFRS Cash Flow Statement (cont’d) Consolidated Cash Flow statement (€m) 2021 2022 2023 2024 1H’24 1H’25 Payments for investments in: intangible assets (233) (163) (163) (130) (56) (56) • Investments in intangible property, plant and equipment (69) (58) (97) (80) (35)
STADA Arzneimittel — Investor Presentation (August 2025) on 6ix